Skip to main content

Table 3 Univariable and multivariable analyses to assess variables independently associated with favorable neurological outcome at 3 months

From: Acute kidney injury after cardiac arrest

Variable

Favorable neurological outcome (n = 81)

Poor neurological outcome (n = 118)

Univariate analysis

Multivariate analysis

Odds ratio (95% CI)

P -value

Odds ratio (95% CI)

P -value

Acute kidney injury, n (%)

29 (36)

56 (47)

0.664 (0.368, 1.197]

0.17

  

Age, years

58 (49 to 71)

66 (53 to 77)

0.981 (0.963, 0.999)

0.04

0.963 (0.937, 0.990)

0.007

Weight, kgs

77 (70 to 90)

75 (65 to 85)

1.012 (0.993, 1.031)

0.24

  

Male, n (%)

63 (78)

71 (60)

2.622 (1.341, 5.126)

0.005

  

Witnessed CA

70 (87)

78 (66)

2.695 (1.283, 5.664)

0.009

  

Bystander CPR, n (%)

60 (74)

52 (44)

2.823 (1.526, 5.224)

0.001

3.682 (1.522, 8.908)

0.004

Time to ROSC, min

13 (7 to 21)

18 (10 to 27)

0.980 (0.958, 1.002)

0.07

1.085 (1.009, 1.167)

0.03

Epinephrine, mg

3 (1 to 5)

5 (3 to 7)

0.846 (0.766, 0.935)

0.001

0.594 (0.439, 0.804)

0.001

Out- of-hospital CA

45 (56)

76 (64)

0.836 (0.465, 1.503)

0.55

  

Non-cardiac origin CA

18 (22)

51 (43)

0.297 (0.150, 0.586)

<0.001

  

VF/VT, n (%)

52 (64)

29 (25)

3.858 (2.925, 4.710)

<0.001

3.797 (2.922, 4.539)

<0.001

Infection during ICU stay, n (%)

49 (60)

74 (63)

1.165 (0.640, 2.121)

0.63

  

IABP during ICU stay, n (%)

6 (7)

9 (8)

1.137 (0.388, 3.334)

0.82

  

ECMO during ICU stay, n (%)

10 (12)

12 (10)

1.193 (0.483, 2.943)

0.70

  

Shock during ICU stay, n (%)

36 (44)

67 (57)

0.531 (0.296, 0.950)

0.03

0.433 (0.187, 0.998)

0.049

Corticosteroid therapy, n (%)

10 (12)

19 (16)

0.720 (0.309, 1.677)

0.45

  

Chronic heart failure, n (%)

20 (24)

37 (31)

0.502 (0.255, 0.989)

0.05

  

Hypertension, n (%)

28 (35)

49 (42)

0.786 (0.433, 1.426)

0.43

  

Coronary artery disease, n (%)

37 (46)

49 (42)

1.093 (0.612, 1.952)

0.76

  

Diabetes, n (%)

16 (20)

26 (22)

0.705 (0.340, 1.462)

0.35

  

COPD/asthma, n (%)

17 (21)

20 (17)

1.190 (0.574, 2.470)

0.64

  

Neurological disease, n (%)

9 (11)

21 (18)

0.686 (0.296, 1.589)

0.38

  

Chronic renal disease, n (%)

11 (14)

19 (16)

0.813 (0.358, 1.846)

0.62

  

Liver cirrhosis, n (%)

2 (2)

9 (8)

0.358 (0.075, 1.704)

0.19

  

Vasopressor therapy, n (%)

50 (62)

84 (71)

0.628 (0.342, 1.151)

0.13

  

Duration of vasopressor therapy, days

4 (2 to 5)

3 (2 to 5)

1.032 (0.918, 1.159)

.060

  

Cumulative vasopressor dose, mcg

10.5 (3.8, 28.8)

31.0 (11.1, 101.8)

0.992 (0.986, 0.999)

0.02

  

Dobutamine therapy, n (%)

39 (48)

55 (47)

0.900 (0.650, 1.246)

0.53

  

Cumulative dobutamine dose, mcg

964 (274 to 1978)

1746 (722 to 3378)

1.002 (1.001, 1.009)

0.04

  

Duration of MV, days

3 (2 to 5)

3 (2 to 5)

1.052 (0.975, 1.136)

0.19

  

CRRT, n (%)

11 (14)

13 (58)

1.491 (0.631, 3.525)

0.36

  

Lactate on admission, mEq/L

2.4 (1.6, 3.8)

3.8 (2.1, 6.8)

0.844 (0.758, 0.940)

0.002

0.864 (0.746, 0.999)

0.049

Fluid balance at 48 h, mL

3714 (1867 to 5970)

4197 (2575 to 6729)

1.199 (0.875, 1.342)*

0.53

  

CrCl on day 1, mL/min

54 (23 to 92)

33 (11 to 78)

1.002 (0.998, 1.007)

0.32

  
  1. Results are expressed as median (IQR) or number (%). *Per liter of fluid balance. CA, cardiac arrest; CPR, cardiopulmonary resuscitation; ROSC, return of spontaneous circulation; VF/VT, ventricular fibrillation/ventricular tachycardia; COPD, chronic obstructive pulmonary disease; IABP, intra-aortic balloon pump counterpulsation; ECMO, extracorporeal membrane oxygenation; MV, mechanical ventilation; CVVH, continuous veno-venous hemofiltration; CrCl, creatinine clearance.
Back to article page

Critical Care

ISSN: 1364-8535